Compare
Jyong Biotech Ltd. vs Emmaus Life Sciences, Inc. vs Propanc Biopharma, Inc. vs Gain Therapeutics, Inc.
| Latest fiscal year | Jyong Biotech Ltd. MENS | Emmaus Life Sciences, Inc. EMMA | Propanc Biopharma, Inc. PPCB | Gain Therapeutics, Inc. GANX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | n/a | $12.45M | n/a | n/a |
| Revenue growth (YoY) | n/a | -25.2% | n/a | n/a |
| Gross margin | n/a | 93.1% | n/a | n/a |
| Operating margin | n/a | 1.9% | n/a | n/a |
| Net margin | n/a | -60.2% | n/a | n/a |
| Net income | -$4.67M | -$7.49M | -$18.86M | -$20.16M |
| EPS (Diluted) | -$0.06 | -$0.12 | -$17.62 | -$0.61 |
| Operating cash flow | -$3.04M | -$11.0K | -$5.68M | -$18.47M |
| Free cash flow | n/a | -$12.0K | -$5.69M | n/a |
| Cash & equivalents | n/a | $2.13M | n/a | $20.84M |
| Total assets | $20.78M | $21.44M | $12.78M | $22.82M |
| Total liabilities | $45.68M | $85.04M | $3.38M | $4.25M |
| Shareholders' equity | -$24.91M | -$63.61M | $9.40M | $18.56M |
| Return on year-end equity | n/a | n/a | -200.6% | -108.6% |
| Shares outstanding | 76.03M | 70.19M | 3.31M | 42.07M |
Revenue, most recent five fiscal years
| Fiscal year | Jyong Biotech Ltd. | Emmaus Life Sciences, Inc. | Propanc Biopharma, Inc. | Gain Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $12.45M Ended 2025-12-31 | n/a | $55.2K Ended 2023-12-31 |
| 1 year earlier | n/a | $16.65M Ended 2024-12-31 | n/a | $140.1K Ended 2022-12-31 |
| 2 years earlier | n/a | $29.60M Ended 2023-12-31 | n/a | $165.0K Ended 2021-12-31 |
| 3 years earlier | n/a | $18.39M Ended 2022-12-31 | n/a | $28.9K Ended 2020-12-31 |
| 4 years earlier | n/a | $20.61M Ended 2021-12-31 | n/a | n/a |